Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritic patients

Abstract

The present disclosure relates to methods, uses, medicaments, pharmaceutical formulations, dosage forms, and kits for inhibiting the progression of structural damage in psoriatic arthritis (PsA) patients using IL-17 antagonists, e.g., IL-17 antibodies and antigen-binding fragments thereof, e.g., secukinumab.

1 . A method of inhibiting the progression of structural damage in a PsA patient, comprising selectively administering 75 mg to 300 mg of an IL-17 antagonist to a patient in need thereof by subcutaneous administration, wherein the IL-17 antagonist is secukinumab, and wherein the patient is selected for treatment with the dose of about 75 mg to 300 mg based on the patient previously failing treatment with a Tumor Necrosis Factor (TNF) alpha antagonist or previously responding inadequately to treatment with a TNF alpha antagonist. 
     
     
         2 .- 6 . (canceled) 
     
     
         7 . The method according  claim 1 , wherein inhibition of the progression of structural damage is measured by the van der Heijde psoriatic arthritis-modified total Sharp score (mTSS). 
     
     
         8 .- 10 . (canceled) 
     
     
         11 . The method according  claim 1 , wherein the patient has concomitant psoriasis. 
     
     
         12 . The method according  claim 1 , wherein inhibiting the progression of structural damage is defined as a change from baseline in mTSS≤0.5. 
     
     
         13 - 18 . (canceled) 
     
     
         19 . The method according to  claim 1 , wherein secukinumab is s.c. administered to the patient at about 75 mg, or about 150 mg or about 300 mg weekly during weeks 0, 1, 2, 3, and 4 and thereafter at about 150 mg or about 300 mg every 4 weeks. 
     
     
         20 . The method according claim  17 , wherein secukinumab is s.c. administered to the patient at about 75 mg, or about 150 mg or about 300 mg monthly. 
     
     
         21 .- 28 . (canceled)